• Recruiting

NCT04445701: Phase 1/2: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dex RRMM

Updated: May 25


NCT04445701: Phase 1/2: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma


a0176

Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma


Open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK)/pharmacodynamics and initial efficacy of AO-176 as monotherapy and in combination with dexamethasone and bortezomib in adults with relapsed/refractory multiple myeloma (MM).


Sponsor

Arch Oncology

 

ClinicalTrials.gov Identifier: NCT04445701


Official Title: A Phase 1/2, Dose Escalation Safety and Tolerability Study of AO-176 as Monotherapy and in Combination With Bortezomib and Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma


First Posted : June 24, 2020


Click here to see details on ClinicalTrials.gov

 

Drug: AO-176 Drug: AO-176 + Dex

Drug: AO-176 + Dex + Bort

AO-176

Anti-CD47 Monoclonal Antibody AO-176 (Code C159600)

Anti-CD47 Monoclonal Antibody AO-176

AO 176

AO-176

AO176

 

Locations

United States, Arizona

United States, Florida

United States, Georgia

United States, Massachusetts

United States, Minnesota

United States, Washington

United States, Wisconsin

Posts Archive